Product science / NAC
N-acetylcysteine alone, by mouth
The science of NAC
What the studies measured and what they found.

Randomized trials only
In the trials: fewer exacerbations of chronic bronchitis and COPD, also with 600 mg per day or less.
To find out what the supplement does, the only useful studies are those in which chance decides who takes NAC and who takes an identical capsule without NAC. This page counts only those, with NAC taken alone by mouth.
NAC has been studied in many diseases. The best results are in the lungs, with doses close to the product's. In many other areas, the trials used 3 to 8 times more and saw no clear difference.
- 3 of 115
- benefits graded A or B
- 86 of 115
- results with no clear effect or with varied results
What is best confirmed
- BGood results Fewer exacerbations of chronic bronchitis Review of 10 studies, in chronic bronchitis About 19% fewer
- BGood results Fewer people with exacerbations in COPD 11 studies, 2,609 people with COPD or chronic bronchitis About 13% fewer
- ASafe Side effects no different from placebo 8 studies, 2,297 people with COPD or chronic bronchitis No increase
Promising results, still to be confirmed
With glycine, on another page
See all 115 resultsNAC / Evidence in humans
How to read the grades, arrows and counts
The arrow shows the direction of the measure: down when the measure fell, for example bronchitis exacerbations. It turns green when the change is an improvement. When the size was assessed, 1, 2 or 3 filled arrows mean a small, moderate or large effect. The = sign means no clear difference.
Few studies: only 1 or 2 controlled trials measured this result. Mixed results: the trials disagree.
When sorting by effect, the result with the largest magnitude in each topic counts. In a tie, the better grade of that result counts first, then alphabetical order. “Largest improvement with NAC” considers benefits in comparisons where the effect of NAC can be isolated. “Largest measured effect” also includes markers.
The grade says how well it works: A, it works and is well studied; B, good results; C, few studies (only 1 or 2 controlled trials measured this result) or mixed results (the trials disagree); D, no clear effect. For safety, A and B mean it does not increase risk, C that there are doubts and F that it increases risk. The grade comes from fixed rules: the size of the effect in the main review, the number of trials and people, and the agreement between trials.
Some results come from trials in children and adolescents, or in mixed age groups; the title gives the age. Grades marked as provisional are still awaiting a reading of the full text or a final check.
The three arrows point in the direction of the measure. When the review documents the magnitude, one, two or three dark arrows correspond to a small, moderate or large effect. For other changes, one dark arrow shows only the direction.
The = sign means the test did not detect a difference. “Varied results” means the results diverged between studies, tests or time points. The counts are of publications; one trial can give rise to several articles.
The records summarize the full text of each article; those that could only be based on the abstract say so under limitations. When a result comes from a review, the review is shown. This is a targeted selection, not a new systematic review. Studies with glycine and NAC taken together are on the GlyNAC page. Left out of the table are NAC given intravenously, inhaled, or applied to the skin or in the mouth, studies without a comparison group, and topics with fewer than 3 trials and no review of their own, such as sleep apnea, ulcerative colitis or strength in older adults.
| Topic | Measured result | Grade | Effect | Evidence |
|---|
What dose was studied?NAC 600 mg In the lungs, close to the product's dose See details
Did the trials use the product's dose?
1 capsule of NAC 600 mg contains 600 mg of NAC. In COPD, with 600 mg per day or less, there were about 16% fewer people with exacerbations, in 8 studies with 1,372 people. In chronic bronchitis, the doses were 400 to 1,200 mg per day.
Many trials in other areas, such as mental health, used 1,800 to 4,800 mg per day. The page gives the dose for each result.
See the lung studiesStomach complaintsWith high doses Mild See details
What was seen in the trials?
With doses of 1.2 to 2.7 g per day, nausea and heartburn were more frequent than with placebo: for example, 41 of 59 people versus 25 of 61, with 2 g per day. In 8 studies with 2,297 people with COPD or chronic bronchitis, side effects were as frequent as with placebo.
If you notice stomach discomfort, take the capsules with a meal.
See the safety studiesGlyNACGlycine + NAC together It has its own page See details
What about GlyNAC?
Trials with glycine and NAC taken together (GlyNAC) are on the GlyNAC page. In a trial with 24 older adults with low glutathione, glutathione more than tripled in 16 weeks in the GlyNAC group; in the placebo group it did not change.
See the GlyNAC pageFrequently Asked Questions
Does it help in chronic bronchitis?
Yes, with fewer exacerbations.
In a review of 10 studies in people with chronic bronchitis, NAC led to about 19% fewer exacerbations than placebo, also in the trials with less than 1,200 mg per day.
See the lung studiesWhat about COPD?
Fewer people with exacerbations.
In a review of 11 studies with 2,609 people with COPD or chronic bronchitis, there were about 13% fewer people with exacerbations; with 600 mg per day or less, about 16% fewer. The air blown out in the first second (FEV1) did not change: the effect is on exacerbations, not on lung capacity.
See the lung studiesDoes it help you get pregnant?
In PCOS, together with fertility treatment, there were more pregnancies.
In women with polycystic ovary syndrome undergoing ovulation induction, adding NAC to treatment led to more pregnancies in 4 of 5 trials, with 778 women. In the largest, 78% became pregnant with NAC, versus 58% without NAC, with 1,800 mg per day for 5 days in each cycle. The grade is still provisional and the result does not apply to fertility in general: in IVF and in semen quality there was no clear difference.
See the PCOS studiesDoes it help with mood or addictions?
Not clearly.
In depression, bipolar disorder, obsessive-compulsive disorder and addictions (alcohol, cannabis, cocaine and tobacco), the trials with NAC found no clear difference compared with placebo. In schizophrenia the results were mixed, and in trichotillomania a small trial was in favor.
See the mental health studiesIs it safe?
Yes, in trials with thousands of people.
In 8 studies with 2,297 people with COPD or chronic bronchitis, side effects were as frequent with NAC as with placebo. In the 2 GlyNAC trials no problems were reported. With high doses, nausea and heartburn are more frequent. If you have a serious lung disease or take medicines, talk to your doctor before starting.
See the safety studiesFor GlyNAC, which is glycine and NAC taken together, see the GlyNAC page.
INSYGMA Labs · 19 November 2026 · Back to top ↑



